1. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
   Mo Shen et al, 2022, Frontiers in Oncology CrossRef
2. The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
   Yan Liu et al, 2021, Cancer Management and Research CrossRef
3. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
   Yongchun Zhou et al, 2021, Frontiers in Oncology CrossRef
4. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
   Firas Batrash et al, 2023, Experimental Hematology & Oncology CrossRef
5. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
   Liyuan Gao et al, 2022, Frontiers in Genetics CrossRef